U.S. markets closed
  • S&P 500

    4,538.43
    -38.67 (-0.84%)
     
  • Dow 30

    34,580.08
    -59.71 (-0.17%)
     
  • Nasdaq

    15,085.47
    -295.85 (-1.92%)
     
  • Russell 2000

    2,159.31
    -47.02 (-2.13%)
     
  • Crude Oil

    66.22
    -0.28 (-0.42%)
     
  • Gold

    1,782.10
    +21.40 (+1.22%)
     
  • Silver

    22.57
    +0.25 (+1.12%)
     
  • EUR/USD

    1.1317
    +0.0012 (+0.10%)
     
  • 10-Yr Bond

    1.3430
    -0.1050 (-7.25%)
     
  • GBP/USD

    1.3235
    -0.0067 (-0.50%)
     
  • USD/JPY

    112.8000
    -0.4090 (-0.36%)
     
  • BTC-USD

    52,880.53
    -3,340.71 (-5.94%)
     
  • CMC Crypto 200

    1,367.14
    -74.62 (-5.18%)
     
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

AC Immune's (ACIU) Stock Up Despite Mixed Data From AD Study

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

AC Immune’s ACIU shares jumped 16.3%, following the company’s announcement of mixed results from phase II Lauriet study evaluating semorinemab — a monoclonal anti-tau antibody — as a potential treatment for mild-to-moderate Alzheimer’s disease (“AD”).

Ac Immune’s stock has rallied 57.3% so far this year in comparison with the industry’s 1.2% increase.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

The Lauriet Study (n=272) evaluated the safety and efficacy of semorinemab in comparison with placebo over a period of 49 weeks. Data from the study demonstrated that semorinemab achieved a statistically significant reduction in one out of two co-primary endpoints. While the study achieved one co-primary endpoint of reduction in cognitive decline by 43.6%, there was no effect on the other co-primary endpoint of reduction in functional decline. The study also did not achieve its secondary endpoints, which evaluated cognitive and functional measures.

The candidate has been developed in collaboration with Genentech, a member of the Roche Group RHHBY. Genentech will continue to evaluate the antibody in the open label portion of the study. The company also anticipates presenting the data from the study at a presentation in November 2021.

Semorinemab targets the N-terminal portion of the tau protein. In AD, tau misfolds and forms tangles, which cause cell damage and ultimately neuronal death. The antibody is designed to bind to tau and slow its spread between neurons.

We also inform investors that the company also conducted another phase II Tauriel study, which evaluated semorinemab in prodromal-to-mild AD. This study, however, did not achieve its primary efficacy endpoint.

The AD space has been in focus of late, following FDA’s approval of Biogen's BIIB Aduhelm, making it the first medicine to be approved to reduce the clinical decline associated with AD in June.

Prothena PRTA is also developing its investigational anti-tau antibody, PRX005, in collaboration with Bristol-Myers, as a potential treatment for AD. A phase I study has also been initiated with PRX005.

AC Immune SA Price

AC Immune SA Price
AC Immune SA Price

AC Immune SA price | AC Immune SA Quote

Zacks Rank

AC Immune presently carries a Zacks Rank #4 (Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Biogen Inc. (BIIB) : Free Stock Analysis Report

Roche Holding AG (RHHBY) : Free Stock Analysis Report

Prothena Corporation plc (PRTA) : Free Stock Analysis Report

AC Immune SA (ACIU) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research